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Summary Differences in the prevalence and spectrum of HIV-associated ophthalmic disease in Africa and Asia are
not well documented. We studied two comparable cohorts of patients initiating antiretroviral therapy in
Mumbai, India, and Cape Town, South Africa. The prevalence of HIV-associated ophthalmic disease
was higher in the Indian population (17.5%) than in the South African population (12.1%). This was
largely because of vitreo-retinal opportunistic infections (11.4% vs. 2.6%, respectively), notably
cytomegalovirus retinitis. This difference persisted after adjusting for confounding factors (adjusted odds
ratio = 11.32, 95% conﬁdence interval: 2.67–48.13), conﬁrming a marked geographical difference in
the prevalence of HIV-associated retinal disease.
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HIV-associated eye disease is estimated to affect 50–75%
of HIV-infected people worldwide at some point during
their disease course (Kestelyn & Cunningham 2001). In
resource-limited settings, patients typically start antiretro-
viral therapy (ART) at low CD4 counts and may be at high
risk of ocular opportunistic infections (OIs). Retinal OIs
such as cytomegalovirus retinitis (CMVR) can lead to
chronic visual impairment or blindness if untreated.
Additionally, immune reconstitution phenomena such as
immune recovery uveitis after ART initiation may increase
ocular morbidity (Karavellas et al. 1998; Price et al. 2001).
Identiﬁcation and treatment of ocular disease in HIV-
infected individuals is therefore important.
Reports suggest that the prevalence and spectrum of
HIV-related eye disease differs geographically. In Asia, the
predominant manifestation is CMVR, followed by other
retinal OIs. Estimates are highest in south-east Asia, where
CMVR affects 27–33% of HIV-infected individuals
(Biswas et al. 2000; Ausayakhun et al. 2003; Gharai et al.
2008; Shah et al. 2008; Pathai et al. 2009). In contrast, the
reported prevalence of CMVR in sub-Saharan Africa is low
(0–16.5%), whereas complications affecting the anterior
segment of the eye such as herpes zoster and molluscum
contagiosum are more frequently reported (Lewallen et al.
1994; Jaffar et al. 1999; Kestelyn 1999). However, it is
difﬁcult to draw ﬁrm conclusions about these differences as
study populations have differed with regard to levels of
immunodeﬁciency, ART exposure and methods of case
ascertainment.
We previously reported on the prevalence of ophthalmic
disease among patients enrolling in an ART service in
Mumbai, India (Pathai et al. 2009), and have since
implemented the same study protocol, using the same study
personnel, in a comparable cohort of patients starting
treatment in a well-characterised ART service in Cape
Town, South Africa (Lawn et al. 2006, 2007). The aim of
this paper was to directly compare the proﬁle of HIV
ocular manifestations in these two populations.
Data collection comprised demographic information,
standardised ocular symptom screening and a full
*Re-use of this article is permitted in accordance with the
Terms and Conditions set out at http://wileyonlinelibrary.com/
onlineopen#OnlineOpen_Terms.
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previously detailed (Pathai et al. 2009). Prevalence of HIV
ocular disease was estimated, and factors associated with
disease were compared between sites using the chi-squared
test. Multiple logistic regression analysis was used to
examine associations between retinal OIs and demo-
graphic⁄clinical characteristics. Three hundred and six
patients were studied (157 in Cape Town and 149 in
Mumbai). Patients from the African and Indian study sites
had similar demographic and clinical characteristics
although the Cape Town cohort had a lower median CD4
cell count (Table 1).
The prevalence of overall HIV-related eye disease was
higher in the Mumbai (17.5%) than in the Cape Town
cohort (12.1%; Table 2). The evidence for a difference was
strongest among those with CD4 count <200 cells⁄ll and
those with advanced WHO clinical stage. When stratifying
by speciﬁc diagnoses, it was clear that the overall difference
was largely because of the higher prevalence of retinal OIs
in the Mumbai cohort, speciﬁcally CMVR (Table 2).
The difference in the risk of retinal OI between sites
persisted after adjusting for age, gender and other a priori
confounders (CD4 count, WHO clinical stage, visual
impairment and ocular symptoms), with an adjusted odds
ratio = 11.32, 95% conﬁdence interval (CI): 2.67–48.13
(Table 3). In addition, low CD4 cell counts and advanced
WHO clinical stages of disease were also independently
associated with the prevalence of retinal OIs (Table 1).
Our data conﬁrm that the spectrum of HIV-related eye
disease differs between these two study sites in India and
Africa. The use of identical study protocols and study
personnel, as well as demographically and clinically similar
study populations, suggests that these ﬁndings can be
reliably compared. The low prevalence of retinal OIs
within the Cape Town cohort (2.6%) is consistent with
other data from the region (Lewallen et al. 1994; Jaffar
et al. 1999; Kestelyn 1999). Similarly, our prevalence
estimate of CMVR in Mumbai is in agreement with other
reports from Asia (Biswas et al. 2000; Ausayakhun et al.
2003; Gharai et al. 2008; Shah et al. 2008).
A previously proposed hypothesis for this difference is
that patients with advanced immunodeﬁciency in the
African region have high mortality and do not survive to
develop CMVR and other complications (Jaffar et al.
1999). However, this would not explain our ﬁndings
whereby the geographical location was a strong indepen-
dent predictor of the prevalence of ophthalmic disease after
adjustment for CD4 cell count and WHO stage of disease.
Previous studies have shown that CMV seroprevalence is
similar in the two populations (Kothari et al. 2002;
Cannon et al. 2010; Chakraborty et al. 2010; Rabenau
et al. 2010), suggesting lack of exposure to CMV within
the Cape Town cohort is an unlikely reason for this
difference. The disparities in prevalence are unclear but
could potentially be related to genetic differences at the
host or virus level (Jabs 1995; Jaffar et al. 1999). There are
no reports to date of geographical differences in the
epidemiology of non-ocular systemic CMV disease, possi-
bly suggesting that host ophthalmic factors may also be
involved. The prevalence of HIV retinopathy was similar in
both groups, and these non-infectious retino-vascular
pathological processes may occur independently of CMV-
mediated mechanisms.
In conclusion, the higher prevalence of HIV-associated
ophthalmic disease in the Indian study population was
largely because of the higher prevalence of CMVR. Further
studies are needed to document other geographical varia-
tions in ocular HIV epidemiology and investigate the
underlying mechanisms. Most cases of CMVR in the
Indian population were not detectable with symptom
screening (Pathai et al. 2009), and this indicates the need
for careful retinal screening in this patient population in
Table 1 Summary characteristics of the
two cohorts of patients enrolling for anti-
retroviral therapy Variable
Cape Town
(n = 157)
Mumbai
(n = 149) P-value
Age (years)
median ± SD
34 ± 10.1 36 ± 8.3 0.12
CD4 count (cells⁄ll)
median (IQR)
143 (59–199) 180 (106–253) 0.01
History of past or current
TB
n, % (95% CI)
80
50.1% (42.8–59.0)
79
53.0% (44.7–61.2)
0.72
WHO clinical stage
3o r4
n, % (95% CI)
99
63.1% (55.0–70.6)
83
55.7% (47.3–63.8)
0.19
SD, standard deviation; n, number; IQR, interquartile range; 95% CI, 95% conﬁdence
interval.
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by ophthalmologists may not be easily available within all
settings, and alternative cost-effective strategies to detect
retinal OIs within this population may need to be devised.
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Table 3 Multivariable analysis to investigate relationship be-
tween HIV-associated vitreo-retinal opportunistic infections and
demographic, clinical and ophthalmic factors
Variable
Multivariable model*
Odds ratio
(95% conﬁdence interval)
P-value
(Wald test)
Gender
Male 1 0.57
Female 0.71 (0.22–2.35)
Age group
(years)
16–30 1 0.5
31–35 1.12 (0.28–4.45)
36–40 0.65 (0.15–2.78)
41–45 0.14 (0.01–1.52)
>46 0.83 (0.17–3.93)
Geographical
location
Cape Town 1 0.001
Mumbai 11.32 (2.67–48.13)
CD4 count
(cells⁄ml)
>200 1 0.02
51–200 1.39 (0.38–5.07)
0–50 6.98 (1.93–31.72)
WHO clinical
stage
1 or 2 1 0.007
3 or 4 17.39 (2.21–137.14)
Visual impairment
None 1 0.07
Present 3.80 (0.89–16.17)
Ocular symptoms
No 1 0.63
Yes 1.49 (0.29–7.57)
*Adjusted for all other factors in model.
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